dpp-4 inhibitor and glp-1 receptor agonist combination Dipeptidyl peptidase-4 Were DPP-4 inhibitors the original
Description
The phase 3 TRIUMPH-4 trial confirmed and extended these findings
Conarello, S
Diabetologia 60, 16391647
My question: given my MS stability but significant metabolic risk factors (obesity, pre-diabetes, cholesterol, thyroid), do you think a GLP-1 agonist (such as tirzepatide or semaglutide) would be a reasonable option for me
We lose most of our brown fat as we grow, which is why we shiver in the cold, with lean people usually having more than overweight people
C., Lai, C
